Successful Treatment of Recurrent Small Cell Carcinoma of Urinary Bladder with Pembrolizumab

Overview

Journal IJU Case Rep

Date 2020 Nov 9

PMID 33163917

Citations 4

Authors

Tomoya Hatayama

Tetsutaro Hayashi

Shinji Matsuzaki

Hiroshi Masumoto

Hiroyuki Yanai

Hamidreza Abdi

Jun Teishima

Yasuhisa Hasegawa

Affiliations

Soon will be listed here.

Abstract

Introduction: Small cell carcinoma of urinary bladder is rare and has an aggressive malignant behavior and poor prognosis. Advanced bladder cancers are treated with immune checkpoint inhibitors, however, its efficacy for small cell carcinoma of urinary bladder is unclear.

Case Presentation: A 54-year-old female, diagnosed with clinical stage T2N0M0 small cell carcinoma of urinary bladder, underwent radical cystectomy after three cycles of etoposide-cisplatin neoadjuvant chemotherapy. Despite the fact that pathological examination revealed no residual carcinoma in bladder in her cystectomy specimen, local recurrence of a 60-mm mass detected in the follow-up investigation 7.5 months later. This was completely treated by pembrolizumab without any adverse effects. Immunohistochemical staining revealed that the tumor had no programmed death ligand 1 expression but it showed CD8-positive T-lymphocyte infiltration into the tumor.

Conclusion: Immune checkpoint inhibitors might have curative potentials for treatment of small cell carcinoma of urinary bladder.

Citing Articles

Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report.

Jiang W, Pan C, Guo W, Xu Z, Ni Q, Ruan Y Diagn Pathol. 2023; 18(1):80.

PMID: 37434193 PMC: 10334510. DOI: 10.1186/s13000-023-01369-x.

A Case of Bladder Large Cell Carcinoma with Review of the Literature.

Lopedote P, Yosef A, Kozyreva O Case Rep Oncol. 2022; 15(1):326-337.

PMID: 35529284 PMC: 9035943. DOI: 10.1159/000521607.

The Application Effect of Traditional Chinese Medicine Nursing on General Anesthesia Combined with Epidural Anesthesia and Electric Resection for the Treatment of Bladder Cancer and Its Influence on Tumor Markers.

Wu Y, Zhang Z, Liu Y, Shi G, Ding X Evid Based Complement Alternat Med. 2022; 2022:7178711.

PMID: 35075365 PMC: 8783706. DOI: 10.1155/2022/7178711.

Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab.

Hatayama T, Hayashi T, Matsuzaki S, Masumoto H, Yanai H, Abdi H IJU Case Rep. 2020; 3(6):252-256.

PMID: 33163917 PMC: 7609171. DOI: 10.1002/iju5.12208.

References

Hatayama T, Hayashi T, Matsuzaki S, Masumoto H, Yanai H, Abdi H . Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab. IJU Case Rep. 2020; 3(6):252-256. PMC: 7609171. DOI: 10.1002/iju5.12208. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Kouba E, Cheng L . Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment: A Review. JAMA Oncol. 2017; 3(11):1570-1578. DOI: 10.1001/jamaoncol.2016.7013. View

Erdem G, Ozdemir N, Demirci N, Sahin S, Bozkaya Y, Zengin N . Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin. 2016; 32(6):1013-21. DOI: 10.1185/03007995.2016.1155982. View

Mandelkow T, Blessin N, Lueerss E, Pott L, Simon R, Li W . Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Dis Markers. 2019; 2019:2532518. PMC: 6525886. DOI: 10.1155/2019/2532518. View

Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M . Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol. 2012; 36(2):126-31. DOI: 10.1097/COC.0b013e3182438c71. View

Cheng L, Pan C, Yang X, Lopez-Beltran A, MacLennan G, Lin H . Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004; 101(5):957-62. DOI: 10.1002/cncr.20456. View

Humphrey P, Moch H, Cubilla A, Ulbright T, Reuter V . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1):106-119. DOI: 10.1016/j.eururo.2016.02.028. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

10.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

11.

Niu Q, Lu Y, Xu S, Shi Q, Guo B, Guo Z . Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018; 10:4479-4489. PMC: 6190820. DOI: 10.2147/CMAR.S175286. View

12.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

13.

Veskimae E, Linares Espinos E, Bruins H, Yuan Y, Sylvester R, Kamat A . What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of.... Eur Urol Oncol. 2019; 2(6):625-642. DOI: 10.1016/j.euo.2019.09.003. View

14.

Miller N, Khaki A, Diamantopoulos L, Bilen M, Santos V, Agarwal N . Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol. 2020; 204(1):63-70. PMC: 7289665. DOI: 10.1097/JU.0000000000000761. View

15.

Wilde L, Ali S, Solomides C, Ross J, Trabulsi E, Hoffman-Censits J . Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. Clin Genitourin Cancer. 2017; 15(3):e521-e524. DOI: 10.1016/j.clgc.2016.12.012. View

16.

Choong N, Quevedo J, Kaur J . Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005; 103(6):1172-8. DOI: 10.1002/cncr.20903. View

17.

Kim J, Kwiatkowski D, McConkey D, Meeks J, Freeman S, Bellmunt J . The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur Urol. 2019; 75(6):961-964. DOI: 10.1016/j.eururo.2019.02.017. View

18.

Gelsomino F, Lamberti G, Parisi C, Casolari L, Melotti B, Sperandi F . The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. Cancer Treat Rev. 2019; 79:101887. DOI: 10.1016/j.ctrv.2019.08.003. View